Keeping Track Of Approvals: Cancer, Cancer, And A Two-Week Cancer Review
Executive Summary
The latest drug development news and highlights from our US FDA Performance Tracker.
You may also be interested in...
Accelerated Approval Drugs’ Fate Rests Heavily On Current Therapeutic Landscape When Confirmatory Trials Are Overdue
At advisory committee meeting on Acrotech's two peripheral T-cell lymphoma drugs, FDA reviewers suggest they are more willing to seek product withdrawal for failure to conduct studies with due diligence when there are numerous available therapies.
Finance Watch: Amarin Raises Cash To Boost Vascepa Marketing Under Soon-To-Be Expanded Label
Public Company Edition: Two months before the deadline for the company's sNDA, the US FDA has not indicated it will hold an advisory committee meeting for the triglyceride-lowering drug. Also, Seattle Genetics raises $575m, Atara and Ra bring in $150m each and Cara completes $145.5m offering.
Keeping Track: Accelerated Approval For Tecentriq And A Burst Of Filings And Submissions
The latest drug development news and highlights from our US FDA Performance Tracker.